Foxp3 expression in CD4+ T cells of patients with systemic lupus erythematosus: a comparative phenotypic analysis

Bonelli, Michael; Dalwigk, K; Savitskaya, A; Smolen, Josef S.; Scheinecker, Clemens

doi:10.1136/ard.2007.074690

Cited by 92 publications

(83 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our data seem to differ from those in some previous reports (9,10), but seem to be consistent with those in very recent reports (12,27), of Treg cells in human SLE. The discrepancy may be mainly due to the different definitions of Treg cells used in the different studies.…”

Section: Discussioncontrasting

confidence: 57%

Dysfunctional CD4+,CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon‐α–producing antigen‐presenting cells

Yan¹,

Ye²,

Chen³

et al. 2008

Arthritis & Rheumatism

165

129

View full text Add to dashboard Cite

Objective. To explore whether there are extrinsic factors that impair the suppressive function of CD4؉,CD25؉ regulatory T cells in patients with untreated active systemic lupus erythematosus (SLE).Methods. We studied 15 patients with untreated active SLE, 10 patients with SLE in remission, and 15 healthy control subjects. Percentages of CD4؉,CD25؉, FoxP3؉ Treg cells and levels of forkhead box P3 (FoxP3) protein were analyzed by flow cytometry. Expression of messenger RNA (mRNA) for FoxP3 in purified Treg cell populations was assessed by real-time polymerase chain reaction analysis. Experiments examining Treg cell function in SLE were designed to distinguish primary from secondary T cell dysfunction. Levels of interferon-␣ (IFN␣) in supernatants from the function assays were determined with an IFN-stimulated response element-luciferase reporter assay.Results. The percentage of CD4؉,CD25؉, FoxP3؉ cells in peripheral blood was significantly increased in SLE patients as compared with controls (mean ؎ SEM 9.11 ؎ 0.73% versus 4.78 ؎ 0.43%; P < 0.0001). We found no difference in FoxP3 expression at either the mRNA or protein level in any CD4؉,CD25؉ T cell subset from SLE patients as compared with controls. Antigen-presenting cells (APCs) from SLE patients were responsible for decreased Treg cell activity and could also render dysfunctional Treg cells from healthy control subjects. CD4؉,CD25؉ Treg cells from SLE patients exhibited normal suppressive activity when cultured with APCs from healthy controls. A partial Treg cell blockade effect was induced by the high levels of IFN␣ derived from SLE patient APCs.Conclusion. We suggest that blockade of Treg cell-mediated suppression by IFN␣-producing APCs in SLE patients may contribute to a pathogenic loss of peripheral tolerance in this disease.

show abstract

Section: Discussioncontrasting

confidence: 57%

Dysfunctional CD4+,CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon‐α–producing antigen‐presenting cells

Yan¹,

Ye²,

Chen³

et al. 2008

Arthritis & Rheumatism

165

129

View full text Add to dashboard Cite

show abstract

“…+ T cells were associated negatively with the disease activity or anti-dsDNA antibody titres in SLE patients [14][15][16]. However, recent studies have shown that FoxP3 is also expressed in some CD4 +…”

Section: Foxp3mentioning

confidence: 98%

Imbalance of different types of CD4+forkhead box protein 3 (FoxP3)+ T cells in patients with new-onset systemic lupus erythematosus

Zhao

Jiang

et al. 2013

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…Furthermore, it has been suggested by several studies that regulatory T cells (Treg), as well as its associated cytokines such as interleukin , play a pivotal role in the progression of SLE (Valencia et al 2007;Bonelli et al 2008;Tselios et al 2014;Cai et al 2015a, b).…”

Section: Introductionmentioning

confidence: 99%

Interleukin-35 as a New Biomarker of Renal Involvement in Lupus Nephritis Patients

Liu

2018

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is an autoimmune connective tissue disease with a wide range of clinical presentations. Lupus nephritis (LN) is the most serious manifestation of SLE. , a member of the interleukin-12 family, has been identified as a novel anti-inflammatory cytokine. In the past ten years, the role of IL-35 in inflammatory and autoimmune diseases has been studied extensively. Serum IL-35 levels, however, have not been studied in LN patients. The aim of the study was to determine serum IL-35 levels in SLE patients with and without nephritis, and their clinical values. The study was carried out on 120 SLE patients, which comprised 80 LN patients and 40 SLE patients without nephritis. SLE disease activity was measured according to Systemic Lupus Erythematosus Dis ease Activity Index-2 k (SLEDAI-2 k). Statistical evaluation was based on Mann-Whitney U-test, t-test, chi-square test, Spearman rank correlation test and Pearson's correlation test. The result showed that active SLE patients (n = 65) have lower serum IL-35 levels, compared to inactive SLE patients (n = 55, P < 0.001). Furthermore, serum IL-35 levels were significantly lower in LN patients (n = 80) than SLE patients without nephritis (n = 40, P = 0.013). Serum IL-35 levels had significant correlations with SLEDAI-2k (r = -0.626, P < 0.001) in SLE patients and estimated glomerular filtration rate (eGFR) (r = 0.348, P = 0.002) in LN patients. These results indicate that IL-35 is a potential biomarker of renal involvement in LN patients.

show abstract

Foxp3 expression in CD4+ T cells of patients with systemic lupus erythematosus: a comparative phenotypic analysis

Abstract: Our data suggest that the expression of Foxp3 on CD4(+) T cells in patients with SLE, at least to some extent, reflects the activation of CD4(+) T cells due to underlying disease activity and does not necessarily indicate a functional regulatory T cell capacity.

Cited by 92 publications

References 42 publications

Dysfunctional CD4+,CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon‐α–producing antigen‐presenting cells

Dysfunctional CD4+,CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon‐α–producing antigen‐presenting cells

Imbalance of different types of CD4+forkhead box protein 3 (FoxP3)+ T cells in patients with new-onset systemic lupus erythematosus

Interleukin-35 as a New Biomarker of Renal Involvement in Lupus Nephritis Patients

Contact Info

Product

Resources

About